{"generic":"Glycerol Phenylbutyrate","drugs":["Glycerol Phenylbutyrate","Ravicti"],"mono":{"0":{"id":"jxwos0","title":"Generic Names","mono":"Glycerol Phenylbutyrate"},"1":{"id":"jxwos1","title":"Dosing and Indications","sub":[{"id":"jxwos1b4","title":"Adult Dosing","mono":"<ul><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> in treatment-naive patients, consider residual urea synthetic capacity, dietary protein requirements, and diet adherence in determining initial dose<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (initial, phenylbutyrate-naive) 4.5 to 11.2 mL\/m(2) (5 to 12.4 g\/m(2)) ORALLY daily in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g)<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (initial, phenylbutyrate-naive with residual enzyme activity): 4.5 mL\/m(2) ORALLY daily in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g)<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (switching from sodium phenylbutyrate): total daily dose of sodium phenylbutyrate (g) multiplied by 0.86 equals total daily dose of glycerol phenylbutyrate (mL); take ORALLY in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g) <\/li><\/ul>"},{"id":"jxwos1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in pediatric patients 2 months to younger than 2 years have not been established; use is contraindicated in patients younger than 2 months<\/li><li>Pharmacokinetic and ammonia control data was collected in 4 patients aged 2 months to younger than 2 years. Data were insufficient to establish a safe and effective dose in this age range. For patients younger than 2 months, immature pancreatic exocrine function may impair hydrolysis of glycerol phenylbutyrate, allowing release of phenylbutyrate and subsequent formation of plasma phenylacetate (PAA). It is unknown whether pancreatic and extrapancreatic lipases are sufficient for hydrolysis, and if there is inadequate intestinal hydrolysis, impaired absorption of phenylbutyrate and hyperammonemia could occur.<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> in treatment-naive patients, consider residual urea synthetic capacity, dietary protein requirements, and diet adherence in determining initial dose<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (initial, phenylbutyrate-naive) 4.5 to 11.2 mL\/m(2) (5 to 12.4 g\/m(2)) ORALLY daily in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g)<\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (initial, phenylbutyrate-naive with residual enzyme activity): 4.5 mL\/m(2) ORALLY daily in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g)  <\/li><li><b>Disorder of the urea cycle metabolism, Chronic management:<\/b> (switching from sodium phenylbutyrate): total daily dose of sodium phenylbutyrate (g) multiplied by 0.86 equals total daily dose of glycerol phenylbutyrate (mL); take ORALLY in 3 equally divided doses rounded up to nearest 0.5 mL; MAX 17.5 mL (19 g) <\/li><\/ul>"},{"id":"jxwos1b6","title":"Dose Adjustments","mono":"<ul><li>renal impairment, no dose recommendations specified; close monitoring of ammonia levels recommended on initiation<\/li><li><b>hepatic impairment, moderate to severe:<\/b> initiate at lower end of dosing range and maintain on lowest dose necessary to control ammonia levels<\/li><li><b>geriatric:<\/b> initiate at lower end of dosing range<\/li><\/ul>"},{"id":"jxwos1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Disorder of the urea cycle metabolism, Chronic management<br\/>"}]},"3":{"id":"jxwos3","title":"Contraindications\/Warnings","sub":[{"id":"jxwos3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to phenylbutyrate<\/li><li>pediatric patients less than 2 months of age<\/li><\/ul>"},{"id":"jxwos3b10","title":"Precautions","mono":"<ul><li>hepatic impairment, moderate to severe; dose reductions recommended<\/li><li>intestinal disease resulting in malabsorption of fat; may reduce the control of plasma ammonia; monitoring recommended<\/li><li>neurotoxicity (eg, somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, exacerbation of preexisting neuropathy) may occur; dose reductions recommended if symptoms of vomiting, nausea, headache, somnolence, or confusion emerge<\/li><li>pancreatic insufficiency; may reduce the control of plasma ammonia; monitoring recommended<\/li><li>renal impairment; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jxwos3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jxwos3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jxwos5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (pediatric, 10% or more)<\/li><li><b>Endocrine metabolic:<\/b>Decrease in appetite (adult, 7% to 10% or more; pediatric, 10% or more), Hyperammonemia (adult, 5% to 10% or more; pediatric, 10% or more)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (adult, 10% to 16%; pediatric, 10% or more), Flatulence (adult, 14%), Upper abdominal pain (pediatric, 10% or more)<\/li><li><b>Neurologic:<\/b>Dizziness (adult, 10% or more), Headache (adult, 10% to 14%; pediatric, 10% or more)<\/li><li><b>Other:<\/b>Fatigue (adult, 7% to 10% or more)<\/li><\/ul>"},"6":{"id":"jxwos6","title":"Drug Name Info","sub":{"0":{"id":"jxwos6b17","title":"US Trade Names","mono":"Ravicti<br\/>"},"2":{"id":"jxwos6b19","title":"Class","mono":"Hyperammonemia Agent<br\/>"},"3":{"id":"jxwos6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxwos6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxwos7","title":"Mechanism Of Action","mono":"Glycerol phenylbutyrate, a triglyceride containing 3 phenylbutyrate (PBA) molecules, is released from the glycerol backbone by lipases in the gastrointestinal tract and hydrolyzed to phenylbutyrate (PBA), which is converted by beta-oxidation to form the active moiety, phenylacetate (PAA). PAA conjugates with glutamine (providing 2 molecules of nitrogen) via acetylation in the liver and kidneys to form phenylacetylglutamine (PAGN). Two moles of nitrogen on PAGN provide an alternative to urea for nitrogen waste excretion for patients who cannot synthesize urea due to urea cycle disorders.<br\/>"},"8":{"id":"jxwos8","title":"Pharmacokinetics","sub":[{"id":"jxwos8b23","title":"Absorption","mono":"Tmax, Oral: 8 hours (phenylbutyrate (PBA)); 12 hours (phenylacetate (PAA)); 10 hours (phenylacetylglutamine (PAGN)) <br\/>"},{"id":"jxwos8b24","title":"Distribution","mono":"<ul><li>Protein binding, phenylbutyrate (PBA): 80.6% to 98%<\/li><li>Protein binding, phenylacetate (PAA): 37.1% to 65.6%<\/li><li>Protein binding, phenylacetylglutamine (PAGN): 7% to 12%<\/li><\/ul>"},{"id":"jxwos8b25","title":"Metabolism","mono":"<ul><li>Gastrointestinal tract: extensive<\/li><li>Liver: extent not specified<\/li><li>Kidney: extent not specified<\/li><li>Phenylbutyrate (PBA) (major): inactive<\/li><li>Phenylacetate (PAA): active<\/li><li>Phenylacetylglutamine (PAGN): inactive<\/li><li>inhibitor of CYP2C9, CYP2D6, CYP3A4\/5, CYP1A2, CYP2C8, CYP2C19, and CYP2D6<\/li><\/ul>"},{"id":"jxwos8b26","title":"Excretion","mono":"<ul><li>Renal: 68.9% (adult)<\/li><li>Renal: 66.4% (pediatric)<\/li><li>Total body clearance: 10.9 to 24.4 L\/hr (pediatric)<\/li><\/ul>"}]},"9":{"id":"jxwos9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>must be used with dietary protein restriction<\/li><li>take with food<\/li><\/ul><\/li><li><b>Instillation, gastrostomy tube<\/b><br\/><ul><li>using an oral syringe, administer directly into gastrostomy\/nasogastric tube<\/li><li>flush tube once with 30 mL water and allow to drain; flush a second time with additional 30 mL water to clear tube<\/li><\/ul><\/li><li><b>Nasogastric<\/b><br\/><ul><li>using an oral syringe, administer directly into gastrostomy\/nasogastric tube<\/li><li>flush tube once with 30 mL water and allow to drain; flush a second time with additional 30 mL water to clear tube<\/li><\/ul><\/li><li><b>Oral<\/b><br\/>administer directly into the mouth using oral syringe or dosing cup<br\/><\/li><\/ul>"},"10":{"id":"jxwos10","title":"Monitoring","mono":"<ul><li>decreased fasting plasma ammonia levels are indicative of efficacy<\/li><li>ammonia levels; patients with pancreatic insufficiency or intestinal malabsorption, upon therapy initiation in patients with renal impairment, and with dose adjustments<\/li><\/ul>"},"11":{"id":"jxwos11","title":"How Supplied","mono":"<b>Ravicti<\/b><br\/>Oral Solution: 1.1 GM\/ML<br\/>"},"13":{"id":"jxwos13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to immediately report symptoms of neurotoxicity (eg, somnolence, dysgeusia, hypoacusis, disorientation, memory impairment).<\/li><li>Drug may cause diarrhea, flatulence, abdominal pain, dyspepsia, nausea, or vomiting.<\/li><li>Advise patient to take drug with food.<\/li><\/ul>"}}}